Roche Agrees To Court Conditions For Mircera Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche says it will price Mircera at or below Epogen and pay Amgen a 22.5 percent royalty; Amgen presses for a permanent injunction against drug’s launch.